Acurx Pharmaceuticals
ACXP
9 hedge funds and large institutions have $1.15M invested in Acurx Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.
463% more capital inflows, than outflows
Capital inflows: $1.15M | Capital outflows: $204K
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
2.39% more ownership
Funds ownership: 1.01% → 3.4% (+2.4%)
10% less funds holding
Funds holding: 10 → 9 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Draper Asset Management
Smithtown,
New York
|
+$1.04M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$42.9K |
| 3 |
BlackRock
New York
|
+$39.3K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$13K |
| 5 |
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
|
+$10.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRT Financial
New York
|
-$62K |
| 2 |
Millennium Management
New York
|
-$61K |
| 3 |
Tocqueville Asset Management
New York
|
-$58.8K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$22K |
ACXP Hedge Fund Activity: Q1 2022 in Review
9 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q1 2022, worth a combined $1.15M — up 152% from $455K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ACXP and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was Draper Asset Management, opening a new position worth an estimated $1.04M. The largest seller was HRT Financial, exiting entirely with an estimated $62K sold.
- 9 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q1 2022, down from 10 in Q4 2021.
- Funds reported $1.15M of Acurx Pharmaceuticals stock for Q1 2022, up 152% quarter-over-quarter.
- 3 funds opened new Acurx Pharmaceuticals positions in Q1 2022 and 4 closed out, a net change of -1 holder.
- The largest Acurx Pharmaceuticals buyer in Q1 2022 was Draper Asset Management, an estimated $1.04M added.
- The largest Acurx Pharmaceuticals seller in Q1 2022 was HRT Financial, an estimated $62K sold.
Based on aggregated 13F filings for Q1 2022.